ArticleFrontiers in genetics2019
Prediction of Recurrence in Cervical Cancer Using a Nine-lncRNA Signature.
Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 53 citations in OpenAlex.
- Integrative Long Non-Coding RNA Analysis and Recurrence Prediction in Cervical Cancer Using a Recurrent Neural Network.Diagnostics (Basel, Switzerland) · 2025Article
- Integrating Clinical and Transcriptomic Profiles Associated with Vitamin D to Enhance Disease-Free Survival in Cervical Cancer Recurrence Using the CatBoost Algorithm.Diagnostics (Basel, Switzerland) · 2025Article
- Bidirectional recurrent neural network approach for predicting cervical cancer recurrence and survival.Scientific reports · 2024Article
- RNA-binding proteins signature is a favorable biomarker of prognosis, immunotherapy and chemotherapy response for cervical cancer.Cancer cell international · 2024Article
- Defining new biomarkers for overcoming therapeutical resistance in cervical cancer using lncRNA.Molecular biology reports · 2023Review
- Developing a 5-gene prognostic signature for cervical cancer by integrating mRNA and copy number variations.BMC cancer · 2022Article
- Identifying a cervical cancer survival signature based on mRNA expression and genome-wide copy number variations.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Signature of seven cuproptosis-related lncRNAs as a novel biomarker to predict prognosis and therapeutic response in cervical cancer.Frontiers in genetics · 2022Article
- Development and validation of an autophagy-related long non-coding RNA prognostic signature for cervical squamous cell carcinoma and endocervical adenocarcinoma.Frontiers in oncology · 2022Article
- Construction of a Six-Gene Prognostic Risk Model Related to Hypoxia and Angiogenesis for Cervical Cancer.Frontiers in genetics · 2022Article
- An immune-associated ten-long noncoding RNA signature for predicting overall survival in cervical cancer.Translational cancer research · 2021Article
- Integrative Systems Biology Approaches to Identify Potential Biomarkers and Pathways of Cervical Cancer.Journal of personalized medicine · 2021Article
- Identification of a tumor microenvironment-related gene signature to improve the prediction of cervical cancer prognosis.Cancer cell international · 2021Article
- A novel lncRNA-mRNA-miRNA signature predicts recurrence and disease-free survival in cervical cancer.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- LncRNA ATXN8OS enhances tamoxifen resistance in breast cancer.Open medicine (Warsaw, Poland) · 2021Article
- A 70-Gene Signature for Predicting Treatment Outcome in Advanced-Stage Cervical Cancer.Molecular therapy oncolytics · 2020Article
- Identification of an autophagy-related gene signature for survival prediction in patients with cervical cancer.Journal of ovarian research · 2020Article
- Long non-coding RNA RP11-284F21.9 functions as a ceRNA regulating PPWD1 by competitively binding to miR-769-3p in cervical carcinoma.Bioscience reports · 2020Article
- A prognostic nomogram integrating novel biomarkers identified by machine learning for cervical squamous cell carcinoma.Journal of translational medicine · 2020Article
- A five-mRNA signature associated with post-translational modifications can better predict recurrence and survival in cervical cancer.Journal of cellular and molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveAs a common cancer type in women, cervical cancer remains one of the leading causes of cancer-associated mortalities word wide. Recent evidence has demonstrated the regulatory role of a large number of long non-coding RNAs (lncRNAs) in cervical cancer. Here, we aimed to identify new biomarkers that related with the recurrence through comprehensive bioinformatics analysis.
methodsFirstly, we collected online lncRNA expression data of cervical cancer patients which were divided into training, validation, and test set. Then we developed a nine-lncRNA signature from training set by conducting LASSO Cox regression model along with 10-fold cross validation. The prognostic value of this risk score was validated in all the three sets using Kaplan-Meier analysis, C-index, time-dependent ROC curves and dynamic AUC. Biological function of these lncRNAs in cervical cancer cells were evaluated by performing gene ontology biological process enrichment and Kyoto Encyclopedia of Genes and Genomes signaling pathways analysis.
resultsAccording to the results, a higher predict accuracy was observed in the nine-lncRNA signature than that of FIGO stage in all the three sets. Stratified analysis also demonstrated that the nine-lncRNA signature can predict the recurrence of cervical cancer within FIGO stage. The potential mechanisms underlying the nine-lncRNAs from the signature were also identified according to the gene enrichment analysis.
conclusionIn the present article, we provided a reliable prognostic tool to facilitate the individual management of patients with cervical cancer after treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.